TY  - JOUR
AU  - Ismaili, L
AU  - Refouvelet, B
AU  - Benchekroun, M
AU  - Brogi, S
AU  - Brindisi, M
AU  - Gemma, S
AU  - Campiani, G
AU  - Filipić, Slavica
AU  - Agbaba, Danica
AU  - Esteban, Gerard
AU  - Unzeta, Mercedes
AU  - Nikolić, Katarina
AU  - Butini, Stefania
AU  - Marco-Contelles, Jose
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2916
AB  - Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and β-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years focusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.
PB  - Elsevier Ltd
T2  - Progress in Neurobiology
T1  - Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease
VL  - 151
SP  - 4
EP  - 34
DO  - 10.1016/j.pneurobio.2015.12.003
ER  - 

@article{
author = "Ismaili, L and Refouvelet, B and Benchekroun, M and Brogi, S and Brindisi, M and Gemma, S and Campiani, G and Filipić, Slavica and Agbaba, Danica and Esteban, Gerard and Unzeta, Mercedes and Nikolić, Katarina and Butini, Stefania and Marco-Contelles, Jose",
year = "2017",
abstract = "Alzheimer's disease is a multifactorial and fatal neurodegenerative disorder characterized by decline of cholinergic function, deregulation of other neurotransmitter systems, β-amyloid fibril deposition, and β-amyloid oligomers formation. Based on the involvement of a relevant number of biological systems in Alzheimer's disease progression, multitarget compounds may enable therapeutic efficacy. Accordingly, compounds possessing, besides anticholinergic activity and β-amyloid aggregation inhibition properties, metal chelating and/or nitric oxide releasing properties with additional antioxidant capacity were developed. Other targets relevant to Alzheimer's disease have also been considered in the last years for producing multitarget compounds such as β-secretase, monoamino oxidases, serotonin receptors and sigma 1 receptors. The purpose of this review will be to highlight recent reports on the development of multitarget compounds for Alzheimer's disease published within the last years focusing on multifunctional ligands characterized by tacrine-like and donepezil-like structures.",
publisher = "Elsevier Ltd",
journal = "Progress in Neurobiology",
title = "Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease",
volume = "151",
pages = "4-34",
doi = "10.1016/j.pneurobio.2015.12.003"
}

Ismaili, L., Refouvelet, B., Benchekroun, M., Brogi, S., Brindisi, M., Gemma, S., Campiani, G., Filipić, S., Agbaba, D., Esteban, G., Unzeta, M., Nikolić, K., Butini, S.,& Marco-Contelles, J.. (2017). Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. in Progress in Neurobiology
Elsevier Ltd., 151, 4-34.
https://doi.org/10.1016/j.pneurobio.2015.12.003

Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipić S, Agbaba D, Esteban G, Unzeta M, Nikolić K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. in Progress in Neurobiology. 2017;151:4-34.
doi:10.1016/j.pneurobio.2015.12.003 .

Ismaili, L, Refouvelet, B, Benchekroun, M, Brogi, S, Brindisi, M, Gemma, S, Campiani, G, Filipić, Slavica, Agbaba, Danica, Esteban, Gerard, Unzeta, Mercedes, Nikolić, Katarina, Butini, Stefania, Marco-Contelles, Jose, "Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease" in Progress in Neurobiology, 151 (2017):4-34,
https://doi.org/10.1016/j.pneurobio.2015.12.003 . .

TY  - JOUR
AU  - Butini, Stefania
AU  - Nikolić, Katarina
AU  - Kassel, S.
AU  - Brueckmann, H.
AU  - Filipić, Slavica
AU  - Agbaba, Danica
AU  - Gemma, S.
AU  - Brogi, S.
AU  - Brindisi, M.
AU  - Campiani, G.
AU  - Stark, Holger
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2738
AB  - Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson's disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Progress in Neurobiology
T1  - Polypharmacology of dopamine receptor ligands
VL  - 142
SP  - 68
EP  - 103
DO  - 10.1016/j.pneurobio.2016.03.011
ER  - 

@article{
author = "Butini, Stefania and Nikolić, Katarina and Kassel, S. and Brueckmann, H. and Filipić, Slavica and Agbaba, Danica and Gemma, S. and Brogi, S. and Brindisi, M. and Campiani, G. and Stark, Holger",
year = "2016",
abstract = "Most neurological diseases have a multifactorial nature and the number of molecular mechanisms discovered as underpinning these diseases is continuously evolving. The old concept of developing selective agents for a single target does not fit with the medical need of most neurological diseases. The development of designed multiple ligands holds great promises and appears as the next step in drug development for the treatment of these multifactorial diseases. Dopamine and its five receptor subtypes are intimately involved in numerous neurological disorders. Dopamine receptor ligands display a high degree of cross interactions with many other targets including G-protein coupled receptors, transporters, enzymes and ion channels. For brain disorders like Parkinson's disease, schizophrenia and depression the dopaminergic system, being intertwined with many other signaling systems, plays a key role in pathogenesis and therapy. The concept of designed multiple ligands and polypharmacology, which perfectly meets the therapeutic needs for these brain disorders, is herein discussed as a general ligand-based concept while focusing on dopaminergic agents and receptor subtypes in particular.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Progress in Neurobiology",
title = "Polypharmacology of dopamine receptor ligands",
volume = "142",
pages = "68-103",
doi = "10.1016/j.pneurobio.2016.03.011"
}

Butini, S., Nikolić, K., Kassel, S., Brueckmann, H., Filipić, S., Agbaba, D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G.,& Stark, H.. (2016). Polypharmacology of dopamine receptor ligands. in Progress in Neurobiology
Pergamon-Elsevier Science Ltd, Oxford., 142, 68-103.
https://doi.org/10.1016/j.pneurobio.2016.03.011

Butini S, Nikolić K, Kassel S, Brueckmann H, Filipić S, Agbaba D, Gemma S, Brogi S, Brindisi M, Campiani G, Stark H. Polypharmacology of dopamine receptor ligands. in Progress in Neurobiology. 2016;142:68-103.
doi:10.1016/j.pneurobio.2016.03.011 .

Butini, Stefania, Nikolić, Katarina, Kassel, S., Brueckmann, H., Filipić, Slavica, Agbaba, Danica, Gemma, S., Brogi, S., Brindisi, M., Campiani, G., Stark, Holger, "Polypharmacology of dopamine receptor ligands" in Progress in Neurobiology, 142 (2016):68-103,
https://doi.org/10.1016/j.pneurobio.2016.03.011 . .